Sudhesh Kumar, MD

itssudhesh@gmail.com

Experience

Resident Physician, Internal MedicineJul 2026 – Present

University of Tennessee Health Sciences, Maury Campus, Columbia, TN

Research Fellow, HematologyAug 2025 – Jun 2026

Mayo Clinic, Rochester, MN

Education

Bachelor of Medicine, Bachelor of Surgery (MBBS)2019 – 2024

Aga Khan University, Karachi, Pakistan

USMLE

Step 1 Pass, Step 2 CK 267, Step 3 235

Publications

Venetoclax Plus Hypomethylating Agent for 7- Versus 14- Versus 21- Versus 28-Day Cycles in Newly-Diagnosed Acute Myeloid Leukemia: ELN and Mayo Genetic Risk-Stratified Analysis in 540 PatientsSep 2026

American Journal of Hematology

Older Age, STAG2, and DNMT3A Mutations Predict Superior Posttransplant Survival in Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating AgentsAug 2026

American Journal of Hematology

Determinants of survival after failure of frontline venetoclax plus hypomethylating agent therapy in 356 patients with newly diagnosed acute myeloid leukemiaAug 2026

Blood Cancer Journal

TP53 Mutations and Circulating Blasts ≥ 20% Are the Primary Determinants of Survival in Accelerated/Blast-Phase Myeloproliferative Neoplasms Treated With Frontline Venetoclax Plus Hypomethylating AgentFeb 2026

American Journal of Hematology

Impact of Drain Placement on Postoperative Complications after Thyroidectomy for Substernal GoiterMar 2024

International Archives of Otorhinolaryngology

Chylothorax as a presentation of Superior Vena Cava syndrome in Fibrosing Mediastinitis: A case reportOct 2023

CHEST

The mid-term and long-term effects of tourniquet use in total knee arthroplasty: systematic reviewDec 2022

Journal of Experimental Orthopaedics

Is minimally invasive orthopedic surgery safer than open? A systematic review of systematic reviewsApr 2022

International Journal of Surgery

Presentations

HMA plus venetoclax for 7- vs 14- vs 21- vs 28-day cycles in newly-diagnosed acute myeloid leukemia: ELN- and Mayo Genetic Risk–stratified analysis in 540 patientsJun 2026

ASCO Annual Meeting, poster session (abstract 6525)

Chylothorax as a presentation of Superior Vena Cava syndrome in Fibrosing MediastinitisMar 2023

Mayo Clinic Internal Medicine Case Conference

Resident Physician, Internal Medicine — University of Tennessee Health Sciences, Maury Campus, Columbia, TN. Jul 2026 – Present
Research Fellow, Hematology — Mayo Clinic, Rochester, MN. Aug 2025 – Jun 2026

Education:

Bachelor of Medicine, Bachelor of Surgery (MBBS), Aga Khan University, Karachi, Pakistan. 2019 – 2024
USMLE Step 1 Pass, Step 2 CK 267, Step 3 235.

Publications:

“Venetoclax Plus Hypomethylating Agent for 7- Versus 14- Versus 21- Versus 28-Day Cycles in Newly-Diagnosed Acute Myeloid Leukemia: ELN and Mayo Genetic Risk-Stratified Analysis in 540 Patients”, American Journal of Hematology. Sep 2026
“Older Age, STAG2, and DNMT3A Mutations Predict Superior Posttransplant Survival in Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents”, American Journal of Hematology. Aug 2026
“Determinants of survival after failure of frontline venetoclax plus hypomethylating agent therapy in 356 patients with newly diagnosed acute myeloid leukemia”, Blood Cancer Journal. Aug 2026
“TP53 Mutations and Circulating Blasts ≥ 20% Are the Primary Determinants of Survival in Accelerated/Blast-Phase Myeloproliferative Neoplasms Treated With Frontline Venetoclax Plus Hypomethylating Agent”, American Journal of Hematology. Feb 2026
“Impact of Drain Placement on Postoperative Complications after Thyroidectomy for Substernal Goiter”, International Archives of Otorhinolaryngology. Mar 2024
“Chylothorax as a presentation of Superior Vena Cava syndrome in Fibrosing Mediastinitis: A case report”, CHEST. Oct 2023
“The mid-term and long-term effects of tourniquet use in total knee arthroplasty: systematic review”, Journal of Experimental Orthopaedics. Dec 2022
“Is minimally invasive orthopedic surgery safer than open? A systematic review of systematic reviews”, International Journal of Surgery. Apr 2022

Presentations:

“HMA plus venetoclax for 7- vs 14- vs 21- vs 28-day cycles in newly-diagnosed acute myeloid leukemia: ELN- and Mayo Genetic Risk–stratified analysis in 540 patients”, ASCO Annual Meeting, poster session (abstract 6525). Jun 2026
“Chylothorax as a presentation of Superior Vena Cava syndrome in Fibrosing Mediastinitis”, Mayo Clinic Internal Medicine Case Conference. Mar 2023